Royalty Pharma Plc's Revenue in the fiscal year 2025 $ 2,378.19 millions
Royalty Pharma Plc's Revenue in the fiscal year 2024 $ 2,263.58 millions
Royalty Pharma Plc's Revenue in the fiscal year 2023 $ 2,354.55 millions
Royalty Pharma Plc's Revenue in the fiscal year 2022 $ 2,237.22 millions
Royalty Pharma Plc's Revenue in the fiscal year 2021 $ 2,289.46 millions
RPRX Revenue second quarter 2026 Y/Y Growth Comment
Royalty Pharma Plc reported Revenue increase of 16.5% year on year in the second quarter 2026, to $ 674.14 millions, this is lower than Royalty Pharma Plc's recent average Revenue surge of 156.85%.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 89 other companies have achieved higher Revenue growth. While Royalty Pharma Plc' s Revenue growth of 16.5% ranks overall at the positon no. 1206 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Royalty Pharma Plc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
4242.86 %
104.4 %
-100 %
(Sep 30 2017)
RPRX's II. Quarter Q/Q Revenue Comment
Royalty Pharma Plc achieved in the II. Quarter 2026 below company average Revenue increase of 6.91% quarter on quarter, to $ 674.14 millions.
II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 1.83% in the II. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue quarter on quarter growth. While Royalty Pharma Plc's Revenue growth quarter on quarter, overall rank is 999.
Royalty Pharma Plc achieved in the II. Quarter 2026 below company average Revenue increase of 6.91% quarter on quarter, to $ 674.14 millions.
II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 1.83% in the II. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue quarter on quarter growth. While Royalty Pharma Plc's Revenue growth quarter on quarter, overall rank is 999.
Royalty Pharma Plc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 2,536.00
$ 2,440.52
$ 2,378.19
$ 2,349.84
$ 2,305.24
Y / Y Revenue Growth (TTM)
10.01 %
7.8 %
5.06 %
3.7 %
3.02 %
Year on Year Revenue Growth Overall
Ranking
# 2274
# 1064
# 1827
# 2582
# 1734
Seqeuential Revenue Change (TTM)
3.91 %
2.62 %
1.21 %
1.93 %
1.83 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2406
# 947
# 1571
# 1002
# 1732
Cumulative Revenue growth Comment
Although Royalty Pharma Plc's Annual Revenue growth year on year were below company's average 309732.79% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.01% year on year, from 7.8% in Mar 31 2026.
In the Healthcare sector 332 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1064 to 2274.
Although Royalty Pharma Plc's Annual Revenue growth year on year were below company's average 309732.79% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.01% year on year, from 7.8% in Mar 31 2026.
In the Healthcare sector 332 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1064 to 2274.
About Royalty Pharma Plc Revenue Growth Rates (RPRX), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
28.74%